Search+Business News›Markets›Stocks›News›Time to re-look at a not-so-glamorous part of healthcare ecosystem: 4 diagnostics stocks with upside potential of up to 18%Investment IdeasSynopsisWhen companies from a sector with a clear growth path get listed, too much money flows into them, sending valuations high. What follows is a long phase of consolidation and valuation readjustment. This readjustment is painful and sparks different narratives – some negative, some positive. So, to reinvest in such a sector, one needs to look beyond narratives.Almost every part of the healthcare ecosystem has been doing well in the market. Hospitals, for one, have been all re-rated by a market that has understood how durable healthcare demand is. One corner of the ecosystem has, however, been left out of that party: Diagnostics. It has been punished for over four years now for the sin of having been too loved during the Covid pandemic. But something in that corner may just have shifted. The ETMarkets.com 12 mins readJul 28, 2026, 01:36:00 PM ISTGift this Story to your friendsFONT SIZEAbcSmallAbcMediumAbcLargeSAVEPRINTCOMMENTContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories & personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions & in-depth stock reportsSubscribe NowETUh-oh! This is an exclusive story available for selected readers only.Worry not. You’re just a step away.What’s Included withETPrime Membership
Time to re-look at a not-so-glamorous part of healthcare ecosystem: 4 diagnostics stocks with upside potential of up to 18%
When companies from a sector with a clear growth path get listed, too much money flows into them, sending valuations high. What follows is a long phase of consolidation and valuation readjustment. This readjustment is painful and sparks different narratives – some negative, some positive. So, to reinvest in such a sector, one needs to look beyond narratives.
Diagnostics stocks, down 4 years post-COVID, offer 18% upside as market rebalances healthcare. Sector normalization signals healthcare budget stabilization—relevant for IT leaders evaluating clinical platform and diagnostics infrastructure investments.







